Key facts
- Solabia’s last known valuation is $1.2B (May 2025).
- Notable investors include Astorg, Famille C Participations.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Solabia
- ·The full record, as it builds
Funding rounds
No funding rounds for Solabia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solabia
Manufacturer of natural active ingredients catering to cosmetic, pharmaceutical, nutraceutical, and microbiology industries. The company incorporates techniques including biocatalysis, enzymatic synthesis, fermentation, and plant extraction to offer culture media, supplements, detection kits, and peptones, thereby meeting the requirements of its customers and its various markets.
- Sector
- Materials and Resources
- HQ
- Paris, France
- Founded
- 1972
- Employees
- 900
- Website
- solabia.com/
- Ownership
- Privately Held (backing)
Solabia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solabia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solabia in its N-PORT filings yet. We sweep new filings monthly.